Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Deferred Revenue (2019 - 2023)

Historic Current Deferred Revenue for Fulcrum Therapeutics (FULC) over the last 5 years, with Q3 2023 value amounting to $600000.0.

  • Fulcrum Therapeutics' Current Deferred Revenue rose 5000.0% to $600000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $600000.0, marking a year-over-year increase of 5000.0%. This contributed to the annual value of $934000.0 for FY2022, which is 8017.41% down from last year.
  • As of Q3 2023, Fulcrum Therapeutics' Current Deferred Revenue stood at $600000.0, which was up 5000.0% from $513000.0 recorded in Q2 2023.
  • In the past 5 years, Fulcrum Therapeutics' Current Deferred Revenue ranged from a high of $14.9 million in Q4 2020 and a low of $400000.0 during Q3 2022
  • For the 5-year period, Fulcrum Therapeutics' Current Deferred Revenue averaged around $4.2 million, with its median value being $2.0 million (2021).
  • As far as peak fluctuations go, Fulcrum Therapeutics' Current Deferred Revenue surged by 27377.79% in 2020, and later plummeted by 8928.19% in 2022.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' Current Deferred Revenue stood at $4.0 million in 2019, then surged by 273.78% to $14.9 million in 2020, then plummeted by 68.4% to $4.7 million in 2021, then crashed by 80.17% to $934000.0 in 2022, then plummeted by 35.76% to $600000.0 in 2023.
  • Its Current Deferred Revenue stands at $600000.0 for Q3 2023, versus $513000.0 for Q2 2023 and $737000.0 for Q1 2023.